Paul Beswick

Discovery, characterisation and optimisation of bicyclic peptide inhibitors that disarm Staphylococcus aureus a-hemolysin

The paper identifies and optimizes bicyclic peptide inhibitors of Staphylococcus aureus α-hemolysin, achieving sub-micromolar affinity and demonstrating functional inhibition of toxin activity.

Investigation of anti-SARS CoV-2 multimeric bicyclic peptide inhibitors in a range of pre-clinical therapeutic settings

This paper evaluates the efficacy of multimeric bicyclic peptides as antiviral agents in preclinical SARS-CoV-2 models, showing significant reduction in viral burden across multiple therapeutic settings.